These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9205801)

  • 1. Selective full dopamine D1-like (SKF-82958) and D2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinsonism.
    Domino EF
    Brain Res Bull; 1997; 43(1):93-5. PubMed ID: 9205801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
    Domino EF; Ni L
    Eur J Pharmacol; 2008 Dec; 599(1-3):81-5. PubMed ID: 18851961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H
    Exp Neurol; 1999 Aug; 158(2):414-21. PubMed ID: 10415147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
    Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
    Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
    Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
    J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R; Bédard PJ; Britton DR; Shiosaki K
    Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
    Domino EF; Ni L; Zhang H; Kohno Y; Sasa M
    Eur J Pharmacol; 1997 May; 325(2-3):137-44. PubMed ID: 9163560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
    Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
    Andringa G; Vermeulen RJ; Drukarch B; Renier WO; Stoof JC; Cools AR
    Behav Pharmacol; 1999 Mar; 10(2):163-73. PubMed ID: 10780829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys.
    Rowlett JK; Platt DM; Yao WD; Spealman RD
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1135-43. PubMed ID: 17351103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.
    Schneider JS; Sun ZQ; Roeltgen DP
    Brain Res; 1994 Nov; 663(1):140-4. PubMed ID: 7850462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats.
    Barrett AC; Miller JR; Dohrmann JM; Caine SB
    Neuropharmacology; 2004; 47 Suppl 1():256-73. PubMed ID: 15464142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.